

Tamara Pringsheim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4817069/publications.pdf>

Version: 2024-02-01

184
papers

14,472
citations

38742
50
h-index

21540
114
g-index

186
all docs

186
docs citations

186
times ranked

19008
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment failure in persistent tic disorders: an expert cliniciansâ€™ consensus-based definition. European Child and Adolescent Psychiatry, 2023, 32, 859-872.	4.7	10
2	Working with parents of children with complex mental health issues to improve care: A qualitative inquiry. Journal of Child Health Care, 2022, 26, 548-567.	1.4	8
3	Influence of sex on tic severity and psychiatric comorbidity profile in patients with pediatric tic disorder. Developmental Medicine and Child Neurology, 2022, 64, 488-494.	2.1	9
4	Paediatric tic-like presentations during the COVID-19 pandemic. Archives of Disease in Childhood, 2022, 107, e17-e17.	1.9	38
5	Alpha agonists for the treatment of Tourette syndrome. International Review of Movement Disorders, 2022, , .	0.1	0
6	Efficacy of Caffeine in <sc>ADCY5</sc>-Related Dyskinesia: A Retrospective Study. Movement Disorders, 2022, 37, 1294-1298.	3.9	16
7	Prognosis of rapid onset functional ticâ€™like behaviors: Prospective followâ€™up over 6 months. Brain and Behavior, 2022, 12, e2606.	2.2	19
8	Transitional Care for Young People with Neurological Disorders: A Scoping Review with A Focus on Patients with Movement Disorders. Movement Disorders, 2021, 36, 1316-1324.	3.9	10
9	Physical activity, sleep and neuropsychiatric symptom severity in children with tourette syndrome. European Child and Adolescent Psychiatry, 2021, 30, 711-719.	4.7	15
10	Children with Tic Disorders Show Greater Variability in an Armâ€™Positionâ€™Matching Proprioceptive Task. Movement Disorders, 2021, 36, 782-784.	3.9	1
11	Bilateral transcranial magnetic stimulation of the supplementary motor area in children with Tourette syndrome. Developmental Medicine and Child Neurology, 2021, 63, 808-815.	2.1	22
12	Implementation and evaluation of a curriculum on the assessment and treatment of disruptive behaviour disorders. Paediatrics and Child Health, 2021, 26, 458-461.	0.6	1
13	The prevalence of depression in adult onset idiopathic dystonia: Systematic review and metaanalysis. Neuroscience and Biobehavioral Reviews, 2021, 125, 221-230.	6.1	14
14	Developing a provincial patient support network for children and families affected by Tourette syndrome and/or obsessiveâ€™compulsive disorder: results of a stakeholder consultation. Child and Adolescent Psychiatry and Mental Health, 2021, 15, 29.	2.5	5
15	Inhibitory Control Deficits in Children with Tic Disorders Revealed by Object-Hit-and-Avoid Task. Neural Plasticity, 2021, 2021, 1-13.	2.2	2
16	Rapid Onset Functional Ticâ€™Like Behaviors in Young Females During the <sc>COVID</sc>-19 Pandemic. Movement Disorders, 2021, 36, 2707-2713.	3.9	85
17	Rapid onset of functional ticâ€™like behaviours in young adults during the COVIDâ€™19 pandemic. European Journal of Neurology, 2021, 28, 3805-3808.	3.3	50
18	Non-pharmacologic interventions to treat apathy in Parkinsonâ€™s disease: A realist review. Clinical Parkinsonism & Related Disorders, 2021, 4, 100096.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. Tremor and Other Hyperkinetic Movements, 2021, 11, 43.	2.0	8
20	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology, 2021, 97, 942-957.	1.1	58
21	Targeted Interventions in Tourette's using Advanced Neuroimaging and Stimulation (TITANS): study protocol for a double-blind, randomised controlled trial of transcranial magnetic stimulation (TMS) to the supplementary motor area in children with Tourette's syndrome. BMJ Open, 2021, 11, e053156.	1.9	5
22	Antidepressant Prescriptions, Including Tricyclics, Continue to Increase in Canadian Children. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 381-388.	1.3	4
23	Prenatal Risk Factors for Tourette Syndrome: a Systematic Review Update. Current Developmental Disorders Reports, 2020, 7, 258-269.	2.1	1
24	Novel Pharmacological Approaches for Tourette Syndrome. Current Developmental Disorders Reports, 2020, 7, 270-276.	2.1	5
25	Diagnosis, treatment and management of apathy in Parkinson's disease: a scoping review. BMJ Open, 2020, 10, e037632.	1.9	37
26	Self-injurious behaviour in movement disorders: systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 712-719.	1.9	19
27	The cognitive neuropsychiatry of Tourette syndrome. Cognitive Neuropsychiatry, 2020, 25, 254-268.	1.3	10
28	Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder. Neurology, 2020, 94, 392-404.	1.1	119
29	Cannabis Use and Internalizing/Externalizing Symptoms in Youth: A Canadian Population-Based Study. Journal of Adolescent Health, 2020, 67, 26-32.	2.5	7
30	Current pharmacotherapy for tic disorders. Expert Opinion on Pharmacotherapy, 2020, 21, 567-580.	1.8	9
31	Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. Tremor and Other Hyperkinetic Movements, 2020, 9, .	2.0	5
32	Barriers and Facilitators Associated with the Management of Aggressive and Disruptive Behaviour in Children: A Qualitative Study with Pediatricians. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 177-187.	0.6	0
33	Practice guideline update summary: Acute treatment of migraine in children and adolescents. Neurology, 2019, 93, 487-499.	1.1	103
34	The Pharmacoepidemiology of Psychotropic Medication Use in Canadian Children from 2012 to 2016. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 740-745.	1.3	17
35	POINT: Is the Term Habit Cough an Inaccurate Use of a Term? Yes. Chest, 2019, 156, 820-821.	0.8	5
36	Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Headache, 2019, 59, 1144-1157.	3.9	28

#	ARTICLE	IF	CITATIONS
37	Practice guideline update summary: Acute treatment of migraine in children and adolescents. Headache, 2019, 59, 1158-1173.	3.9	25
38	New Guidelines: Interpretation, Application and the Future. Headache, 2019, 59, 1133-1143.	3.9	2
39	Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 730-739.	1.3	0
40	Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology, 2019, 93, 500-509.	1.1	91
41	Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 2019, 92, 896-906.	1.1	270
42	Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 2019, 92, 907-915.	1.1	138
43	Treatment Recommendations for Tardive Dyskinesia. Canadian Journal of Psychiatry, 2019, 64, 388-399.	1.9	52
44	Effect of diet, exercise and sleep on tic severity: a scoping review protocol. BMJ Open, 2019, 9, e024653.	1.9	5
45	Rebuttal From Dr Pringsheim. Chest, 2019, 156, 824.	0.8	2
46	Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. Tremor and Other Hyperkinetic Movements, 2019, 9, .	2.0	6
47	Exploring the Decisional needs of Parents with Children with ADHD and Disruptive and Aggressive Behaviour. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2019, 28, 30-41.	0.6	0
48	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 789-800.	1.1	107
49	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 777-788.	1.1	406
50	The Assessment and Treatment of Antipsychotic-Induced Akathisia. Canadian Journal of Psychiatry, 2018, 63, 719-729.	1.9	48
51	Antipsychotic Drug-Induced Movement Disorders: A Forgotten Problem?. Canadian Journal of Psychiatry, 2018, , 070674371877252.	1.9	2
52	Effects of depression and anxiety on quality of life in five common neurological disorders. General Hospital Psychiatry, 2018, 52, 58-63.	2.4	52
53	Barriers and Facilitators for Guidelines with Depression and Anxiety in Parkinson's Disease or Dementia. Canadian Journal on Aging, 2018, 37, 185-199.	1.1	10
54	Validating screening tools for depression in Parkinson's disease. Movement Disorders, 2018, 33, 1184-1186.	3.9	9

#	ARTICLE	IF	CITATIONS
55	Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada. <i>Clinical Drug Investigation</i> , 2018, 38, 449-455.	2.2	28
56	Practice guideline update summary: Mild cognitive impairment. <i>Neurology</i> , 2018, 90, 126-135.	1.1	1,263
57	The lesser of two evils: a qualitative study of quetiapine prescribing by family physicians. <i>CMAJ Open</i> , 2018, 6, E191-E196.	2.4	13
58	Detecting anxiety in individuals with Parkinson disease. <i>Neurology</i> , 2018, 90, e39-e47.	1.1	20
59	Underrepresentation of women in Parkinson's disease trials. <i>Movement Disorders</i> , 2018, 33, 1825-1826.	3.9	25
60	Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. <i>The Cochrane Library</i> , 2018, 2018, CD007990.	2.8	52
61	Second-generation antipsychotics and metabolic side-effects: Canadian population-based study. <i>BJPsych Open</i> , 2018, 4, 256-261.	0.7	8
62	Antipsychotic Drug-Induced Movement Disorders: A Forgotten Problem?. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 717-718.	1.9	9
63	The prevalence of diagnosed obsessive compulsive disorder and associated comorbidities: A population-based Canadian study. <i>Psychiatry Research</i> , 2018, 268, 137-142.	3.3	50
64	Identifying priority outcomes that influence selection of disease-modifying therapies in MS. <i>Neurology: Clinical Practice</i> , 2018, 8, 179-185.	1.6	23
65	Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2018, 91, 373-374.	1.1	25
66	Using antipsychotics for behavioral problems in children. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1475-1488.	1.8	28
67	Tic-related obsessive-compulsive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2018, 43, 431-432.	2.4	21
68	Clinical Utility of Screening for Anxiety and Depression in Children with Tourette Syndrome. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2018, 27, 15-21.	0.6	15
69	Risk factors for the onset and progression of Huntington disease. <i>NeuroToxicology</i> , 2017, 61, 79-99.	3.0	48
70	Clinical Complexity and Use of Antipsychotics and Restraints in Long-Term Care Residents with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 103-115.	2.8	9
71	Health status, health related behaviours and chronic health indicators in people with Tourette Syndrome: A Canadian population-based study. <i>Psychiatry Research</i> , 2017, 250, 228-233.	3.3	15
72	Neurology and mental health. <i>Neurology: Clinical Practice</i> , 2017, 7, 96-97.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Determinants of neurological disease: Synthesis of systematic reviews. <i>NeuroToxicology</i> , 2017, 61, 266-289.	3.0	22
74	Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. <i>Drug Safety</i> , 2017, 40, 771-781.	3.2	136
75	Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder. <i>BJPsych Open</i> , 2017, 3, 141-146.	0.7	2
76	Assessment and Treatment of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents: Creation and Dissemination of a National Curriculum. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 431-432.	1.9	4
77	Functional movement disorders. <i>Neurology: Clinical Practice</i> , 2017, 7, 141-147.	1.6	13
78	Tic Severity and Treatment in Children: The Effect of Comorbid Attention Deficit Hyperactivity Disorder and Obsessive Compulsive Behaviors. <i>Child Psychiatry and Human Development</i> , 2017, 48, 960-966.	1.9	12
79	Prevalence and incidence of epilepsy. <i>Neurology</i> , 2017, 88, 296-303.	1.1	1,141
80	Alternating hemiplegia of childhood. <i>Neurology: Clinical Practice</i> , 2017, 7, 413-414.	1.6	2
81	Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 498-504.	1.4	21
82	Physical Health and Drug Safety in Individuals with Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 673-683.	1.9	22
83	Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 635-647.	1.9	37
84	Canadian Schizophrenia Guidelines: Introduction and Guideline Development Process. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 586-593.	1.9	16
85	Response to Comment on: Tics in the Pediatric Population: Pragmatic Management. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 641-642.	1.5	1
86	Tics in the Pediatric Population: Pragmatic Management. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 160-172.	1.5	61
87	Genetic variation associated with the occurrence and progression of neurological disorders. <i>NeuroToxicology</i> , 2017, 61, 243-264.	3.0	18
88	How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. <i>Headache</i> , 2016, 56, 1194-1200.	3.9	21
89	Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. <i>Headache</i> , 2016, 56, 808-816.	3.9	54
90	Quetiapine use in adults in the community: a population-based study in Alberta, Canada. <i>BMJ Open</i> , 2016, 6, e010861.	1.9	31

#	ARTICLE	IF	CITATIONS
91	A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies. Canadian Journal of Neurological Sciences, 2016, 43, 163-177.	0.5	133
92	The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2016, 46, 292-300.	2.3	473
93	The International Incidence of Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Canadian Journal of Neurological Sciences, 2016, 43, 774-785.	0.5	316
94	Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurology, 2016, 16, 244.	1.8	43
95	Detecting depression in Parkinson disease. Neurology, 2016, 87, 426-437.	1.1	136
96	Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis. Neurology, 2016, 87, 2375-2379.	1.1	48
97	The prevalence of diagnosed tourette syndrome in Canada: A national population-based study. Movement Disorders, 2016, 31, 1658-1663.	3.9	63
98	Aripiprazole for autism spectrum disorders (ASD). The Cochrane Library, 2016, 2016, CD009043.	2.8	92
99	The Prevalence and Incidence of Dementia: a Systematic Review and Meta-analysis. Canadian Journal of Neurological Sciences, 2016, 43, S3-S50.	0.5	134
100	The Prevalence and Incidence of Dementia Due to Alzheimer's Disease: a Systematic Review and Meta-Analysis. Canadian Journal of Neurological Sciences, 2016, 43, S51-S82.	0.5	194
101	Stopping antidepressants following depression. BMJ, The, 2016, 352, i220.	6.0	2
102	Somatic Cough Syndrome (Previously Referred to as Psychogenic Cough) and Tic Cough (Previously) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	76
103	The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents with Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 1: Psychostimulants, Alpha-2 Agonists, and Atomoxetine. Canadian Journal of Psychiatry, 2015, 60, 42-51.	1.9	108
104	The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents with Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 2: Antipsychotics and Traditional Mood Stabilizers. Canadian Journal of Psychiatry, 2015, 60, 52-61.	1.9	75
105	Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in Children and Adolescents with Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, or Conduct Disorder. Canadian Journal of Psychiatry, 2015, 60, 62-76.	1.9	72
106	Health-related behaviors and comorbidities in people with epilepsy: Changes in the past decade. Epilepsia, 2015, 56, 1973-1981.	5.1	17
107	Thiamine prescribing practices within university-affiliated hospitals: A multicenter retrospective review. Journal of Hospital Medicine, 2015, 10, 246-253.	1.4	17
108	Pharmacoepidemiology of Antipsychotic Use in Canadian Children and Adolescents. , 2015, , 13-25.		0

#	ARTICLE	IF	CITATIONS
109	Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks?. <i>BMJ, The</i> , 2015, 350, h569-h569.	6.0	9
110	Two children with tremor. <i>Cmaj</i> , 2015, 187, 512-517.	2.0	1
111	The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2015, 17, 776-783.	1.2	228
112	The future of neurological patient registries. <i>Clinical Practice (London, England)</i> , 2014, 11, 509-516.	0.1	1
113	Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. <i>CMAJ Open</i> , 2014, 2, E225-E232.	2.4	74
114	The international incidence and prevalence of neurologic conditions. <i>Neurology</i> , 2014, 83, 1661-1664.	1.1	60
115	Prenatal risk factors for Tourette Syndrome: a systematic review. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 53.	2.4	65
116	Nutraceuticals for the prevention of migraine in children: Do we know what the benefits and the risks are?. <i>Cephalgia</i> , 2014, 34, 563-564.	3.9	1
117	Prevalence of neurological conditions across the continuum of care based on interRAI assessments. <i>BMC Health Services Research</i> , 2014, 14, 29.	2.2	16
118	A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. <i>Neuromuscular Disorders</i> , 2014, 24, 482-491.	0.6	350
119	The prevalence of Parkinson's disease: A systematic review and meta-analysis. <i>Movement Disorders</i> , 2014, 29, 1583-1590.	3.9	1,532
120	Triptans for symptomatic treatment of migraine headache. <i>BMJ, The</i> , 2014, 348, g2285-g2285.	6.0	17
121	Methodologies for the Development of the Management of Cough. <i>Chest</i> , 2014, 146, 1395-1402.	0.8	29
122	Management and Diagnosis of Psychogenic Cough, Habit Cough, and Tic Cough. <i>Chest</i> , 2014, 146, 355-372.	0.8	42
123	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurology</i> , 2013, 13, 128.	1.8	392
124	The Pharmacoeconomics of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada from 2005 to 2009: A Database Analysis. <i>Paediatric Drugs</i> , 2013, 15, 319-327.	3.1	27
125	Social Behavior and Comorbidity in Children With Tics. <i>Pediatric Neurology</i> , 2013, 49, 406-410.	2.1	12
126	An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. <i>Developmental Medicine and Child Neurology</i> , 2013, 55, 509-519.	2.1	1,056

#	ARTICLE	IF	CITATIONS
127	Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. <i>Neuroepidemiology</i> , 2013, 40, 195-210.	2.3	169
128	Ethical and Legal Considerations for Canadian Registries. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S5-S22.	0.5	8
129	The Case for Neurological Registry Best Practice Guidelines in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S1-S3.	0.5	8
130	Patient Recruitment by Neurological Registries. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S23-S26.	0.5	7
131	Linkage Between Neurological Registry Data and Administrative Data. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S32-S34.	0.5	4
132	Registry Data Storage and Curation. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S35-S40.	0.5	3
133	Neurological Registry Feasibility and Sustainability. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S55-S59.	0.5	3
134	Evaluation of Neurological Patient Registries. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S60-S61.	0.5	1
135	Common Data Elements for Neurological Registries. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S62-S63.	0.5	4
136	Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, s33-s62.	0.5	2
137	Targeted Review: Medications for Acute Migraine Treatment. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S10-S32.	0.5	3
138	Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S33-S62.	0.5	4
139	Neurological Registry Data Collection Methods and Configuration. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S27-S31.	0.5	2
140	Online Neurological Registries. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S41-S45.	0.5	1
141	Neurological Registry Quality Control and Quality Assurance. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S47-S50.	0.5	2
142	Validation and Interpretation of Neurological Registry Data. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S51-S53.	0.5	3
143	Management of comorbid Tourette syndrome and attention-deficit/ hyperactivity disorder: Are psycho-stimulants an option?. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, E11-E12.	2.4	0
144	Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l'utilisation d'antipsychotiques de deuxième génération chez les enfants et les adolescents. <i>Paediatrics and Child Health</i> , 2012, 17, 22B-30B.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy. Canadian Journal of Psychiatry, 2012, 57, 133-143.	1.9	164
146	Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Behavioural Therapy, Deep Brain Stimulation, and Transcranial Magnetic Stimulation. Canadian Journal of Psychiatry, 2012, 57, 144-151.	1.9	135
147	Second-Generation Antipsychotics for the Treatment of Disruptive Behaviour Disorders in Children: A Systematic Review. Canadian Journal of Psychiatry, 2012, 57, 722-727.	1.9	36
148	The prevalence of primary dystonia: A systematic review and meta-analysis. Movement Disorders, 2012, 27, 1789-1796.	3.9	272
149	Reply to letter: Prevalence estimates of Huntington's disease in Caucasian populations are gross underestimates. Movement Disorders, 2012, 27, 1708-1709.	3.9	2
150	Recommendations for optimal ICD codes to study neurologic conditions. Neurology, 2012, 79, 1049-1055.	1.1	164
151	Aripiprazole for autism spectrum disorders (ASD)., 2012, , CD009043.		65
152	Prevalence of Tic Disorders: A Systematic Review and Meta-Analysis. Pediatric Neurology, 2012, 47, 77-90.	2.1	395
153	Des recommandations probantes pour surveiller l'innocuité des antipsychotiques de deuxième génération chez les enfants et les adolescents. Paediatrics and Child Health, 2012, 17, 12B-21B.	0.6	1
154	The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis. Movement Disorders, 2012, 27, 1083-1091.	3.9	477
155	Cochrane Review: Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 1196-1230.	2.0	0
156	Canadian Headache Society guideline for migraine prophylaxis. Canadian Journal of Neurological Sciences, 2012, 39, S1-59.	0.5	166
157	Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. The Cochrane Library, 2011, , CD007990.	2.8	68
158	Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children. Drug Safety, 2011, 34, 651-668.	3.2	117
159	Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 2011, 16, 581-589.	0.6	116
160	The Pharmacoepidemiology of Antipsychotics for Adults with Schizophrenia in Canada, 2005 to 2009. Canadian Journal of Psychiatry, 2011, 56, 630-634.	1.9	9
161	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, , .	0.6	16
162	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 590-598.	0.6	42

#	ARTICLE	IF	CITATIONS
163	Cochrane Review: Pimozide for tics in Tourette's syndrome. Evidence-Based Child Health: A Cochrane Review Journal, 2011, 6, 240-254.	2.0	0
164	Missed Diagnosis of Tardive Dystonia in an Adolescent Girl Treated with Risperidone. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 191-194.	1.3	7
165	The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents: 2005–2009. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 537-543.	1.3	79
166	Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2011, 20, 218-33.	0.6	65
167	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 575-80.	0.6	19
168	Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 2011, 16, 581-9.	0.6	40
169	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 590-8.	0.6	16
170	Pharmacotherapeutics of Tourette Syndrome and Stereotypies in Autism. Seminars in Pediatric Neurology, 2010, 17, 254-260.	2.0	27
171	Prophylaxis of migraine headache. Cmaj, 2010, 182, E269-E276.	2.0	49
172	Complications of Antipsychotic Therapy in Children With Tourette Syndrome. Pediatric Neurology, 2010, 43, 17-20.	2.1	21
173	Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of life. Patient Preference and Adherence, 2009, 3, 251.	1.8	6
174	Understanding disability in Tourette syndrome. Developmental Medicine and Child Neurology, 2009, 51, 468-472.	2.1	61
175	Prenatal and Perinatal Morbidity in Children with Tourette Syndrome and Attention-Deficit Hyperactivity Disorder. Journal of Developmental and Behavioral Pediatrics, 2009, 30, 115-121.	1.1	44
176	Pimozide for tics in Tourette's syndrome. The Cochrane Library, 2009, , CD006996.	2.8	53
177	Acute treatment and prevention of menstrually related migraine headache. Neurology, 2008, 70, 1555-1563.	1.1	87
178	Migraine and Ovarian Sex Hormones, Clinical Abstracts. Headache, 2007, 47, 341-344.	3.9	0
179	Effective treatment of migraine. Postgraduate Medicine, 2004, 115, 28-50.	2.0	4
180	Migraine prevalence in male to female transsexuals on hormone therapy. Neurology, 2004, 63, 593-594.	1.1	52

#	ARTICLE	IF	CITATIONS
181	Tics. Current Opinion in Neurology, 2003, 16, 523-527.	3.6	12
182	Cluster Headache: Evidence for a Disorder of Circadian Rhythm and Hypothalamic Function. Canadian Journal of Neurological Sciences, 2002, 29, 33-40.	0.5	77
183	Melatonin as Adjunctive Therapy in the Prophylaxis of Cluster Headache: A Pilot Study. Headache, 2002, 42, 787-792.	3.9	97
184	In-Patient Treatment of Chronic Daily Headache Using Dihydroergotamine: a Long-term Follow-up Study. Canadian Journal of Neurological Sciences, 1998, 25, 146-150.	0.5	29